10,432 Shares in Evolus, Inc. (NASDAQ:EOLS) Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC purchased a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 10,432 shares of the company’s stock, valued at approximately $115,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tri Locum Partners LP acquired a new stake in shares of Evolus in the 4th quarter worth about $8,198,000. Gilder Gagnon Howe & Co. LLC grew its holdings in Evolus by 287.2% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock worth $7,753,000 after buying an additional 520,859 shares in the last quarter. Caligan Partners LP boosted its holdings in Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after acquiring an additional 498,900 shares during the last quarter. Allostery Investments LP bought a new stake in shares of Evolus in the 4th quarter worth $4,760,000. Finally, Altium Capital Management LLC raised its holdings in shares of Evolus by 93.0% in the fourth quarter. Altium Capital Management LLC now owns 685,000 shares of the company’s stock valued at $7,562,000 after purchasing an additional 330,000 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Analyst Upgrades and Downgrades

EOLS has been the subject of several analyst reports. Barclays increased their price objective on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. BTIG Research started coverage on shares of Evolus in a research report on Thursday, April 17th. They set a “buy” rating and a $21.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, May 8th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $23.75.

Evolus Stock Performance

Shares of EOLS stock opened at $9.68 on Friday. The firm’s 50 day moving average is $10.97 and its 200 day moving average is $12.10. The stock has a market capitalization of $624.13 million, a P/E ratio of -10.64 and a beta of 1.11. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Insider Transactions at Evolus

In other news, CFO Sandra Beaver sold 6,494 shares of the company’s stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $10.02, for a total transaction of $65,069.88. Following the sale, the chief financial officer now directly owns 167,089 shares in the company, valued at $1,674,231.78. This represents a 3.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider David Moatazedi sold 15,787 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $9.87, for a total transaction of $155,817.69. Following the completion of the sale, the insider now owns 492,832 shares in the company, valued at $4,864,251.84. This represents a 3.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 86,241 shares of company stock valued at $1,048,666 over the last three months. Company insiders own 5.90% of the company’s stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.